Although the level of GFAP+ astrocytes in NPC-CM(M)-treatment was slightly lower than that in the NPC-CM(S)-treatment group, the difference was not statistically significant (p > 0.05). This evidence concerns the gene GFAP and nasopharyngeal carcinoma.